Indeed, NCIH2170 exhibits the strongest sensitivity to HER2 inhibitors lapatinib and neratinib among all the lung squamous cancer cell lines tested in the Cancer Therapeutics Response Portal CTD2 project (Fig. 6B). Here, ERBB2 is linked to cancer.